MabVax Therapeutics and Telik join forces

By Angela Sormani — 2 years ago

Cancer immunotherapy company MabVax Therapeutics and Telik, a clinical stage oncology drug development company have entered into a definitive merger agreement. MabVax is backed by Numoda Capital Innovations, Burrill Capital and RTP Venture Fund.


MabVax Therapeutics Secures First Series B Tranche

By Angela Sormani — 3 years ago

MabVax Therapeutics, a privately held clinical stage biotechnology company has closed the first tranche in a Series B financing. Numoda Capital Innovations led the round and was joined by existing investors Burrill Capital Fund IV and RTP Venture Fund for an aggregate investment of $5.25 million.